EGFR and non-small cell lung carcinoma: The National Comprehensive Cancer Network guideline of non-small-cell lung cancer recommended biomarkers favorable for target therapies such as epidermal growth factor receptor (EGFR) mutation (Couraud et al., 2014; Xu et al., 2016).